ALLMedicine™ Fibrolamellar Carcinoma Center

Feb 16th, 2023 - Fibrolamellar Hepatocellular Carcinoma (FLC) is a rare (0.05 per 100,000) subtype of primary liver cancer which predominantly affects younger patients, median age of diagnosis 22-23 years. In patients with advanced stage disease the prognosis is p...

Jan 6th, 2023 - Fibrolamellar carcinoma (FLC) is a rare cancer of the liver that most commonly affects children and young adults. There is no clear standard of care for the disease, whose response to treatment seems to be very different from that of hepatocellula...

Oct 17th, 2022 - Practice Essentials Fibrolamellar carcinoma (FLC) is a primary liver cancer that occurs in adolescents and young adults without underlying liver disease. Although FLC was historically considered to be a histologic variant of hepatocellular carcino...

Oct 17th, 2022 - Practice Essentials Fibrolamellar carcinoma (FLC) is a primary liver cancer that occurs in adolescents and young adults without underlying liver disease. Although FLC was historically considered to be a histologic variant of hepatocellular carcino...

Oct 17th, 2022 - Practice Essentials Fibrolamellar carcinoma (FLC) is a primary liver cancer that occurs in adolescents and young adults without underlying liver disease. Although FLC was historically considered to be a histologic variant of hepatocellular carcino...

Feb 16th, 2023 - Fibrolamellar Hepatocellular Carcinoma (FLC) is a rare (0.05 per 100,000) subtype of primary liver cancer which predominantly affects younger patients, median age of diagnosis 22-23 years. In patients with advanced stage disease the prognosis is p...

Sep 16th, 2022 - This Phase 1 study will enroll up to approximately 195 evaluable adult participants with refractory cancer (solid tumors) regardless of diagnosis. The study will consist of a 3+3 dose escalation. Different dose levels of botensilimab, both monothe...

Sep 6th, 2018 - Primary Objective: • To determine the 6-month progression free survival (PFS6) rate when patients with advanced fibrolamellar carcinoma (FLC) are treated with daily oral ENMD 2076 Secondary Objectives: To evaluate the overall response rate using R...

Mar 13th, 2014 - Fibrolamellar hepatocellular carcinoma is variant rare of hepatocellular carcinoma witch distinct clinical, histological and prognostic features from conventional hepatocellular carcinoma. This entity typically occurs in young adults with no under...

Apr 10th, 2013 - OBJECTIVES: To characterize, at a molecular level, archived samples of tissue from young patients with fibrolamellar carcinoma and hepatocellular carcinoma in non-cirrhotic livers matched for age and sex. To perform genomic analysis on these tissu...

Jun 23rd, 2022 - Key clinical point: The pediatric hepatocellular carcinoma (HCC) subtypes fibrolamellar carcinoma (FLC) and conventional HCC (cHCC) can be considered nonequivalent entities because they show different anatomic patterns and outcomes together with t.

Nov 4th, 2021 - Welcome to OncLive On Air®! I’m your host today, Jason Harris. OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and pr...

Oct 22nd, 2021 - Mark Yarchoan, MD, assistant professor of oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses unique characteristics of fibrolamellar carcinoma (FC). FC is a distinct type of liver cancer, Yarchoan says. Unlik...

Oct 21st, 2021 - Fibrolamellar carcinoma is an extremely rare form of liver cancer that affects approximately 1 in 5 million Americans.1 However, because the disease appears so infrequently, it may be underdiagnosed, said Mark Yarchoan, MD. He added that, with an ...

Oct 6th, 2021 - Ghassan Abou-Alfa, MD While the hepatocellular carcinoma (HCC) field shifted in 2018 with the addition of newly available treatment options, more pivotal research is on the way, said Ghassan K. Abou-Alfa, MD. For a 10-year span, there was only 1...